Drugs / AZD5492
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06916806 | May 2025 → May 2027 expected | idiopathic inflammatory myopathy, rheumatoid arthritis, systemic lupus erythematosus | AstraZeneca | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06542250 | Sep 2024 → Feb 2028 expected | B-cell neoplasm | AstraZeneca | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | AstraZeneca | Results AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024 astrazeneca.com ↗
An oral presentation will share preclinical data demonstrating the anti-tumour activity of AZD5492, a next-generation CD8 selective, CD20-targeting T-cell engager, designed using AstraZeneca’s innovative Target Induced T-cell Activating Nanobody (TITAN) platform. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-07 | AstraZeneca | AstraZeneca showcases strength of haematology portfolio and pipeline at ASH 2024 astrazeneca.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5492 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06542250 ↗ |
| Route | Subcutaneous | “which is administered subcutaneously” NCT06542250 ↗ |